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Background
Stimulators of the nitric oxide (NO) receptor soluble
guanylate cyclase (sGC) are a new class of substances
which enhance the biosynthesis of cyclic guanosin -
monophosphate (cGMP) independently from the pre-
s e n c eo fn i t r i co x i d e( N O ) .I np u l m o n a r ys m o o t hm u s -
cle cells, increased intracellular cGMP concentrations
lead to vasodilatation, making sGC-stimulators poten-
tially useful for the treatment of patients suffering from
pulmonary hypertension (PH). Despite recent advances
in the management of PH there is still significant mor-
bidity and mortality from this condition which may
occur in isolation (idiopathic pulmonary arterial hyper-
tension, iPAH) or in the context of different clinical set-
tings including chronic thromboembolic pulmonary
hypertension (CTEPH), PH in chronic obstructive pul-
monary diseases (PH-COPD), in interstitial lung disease
(PH-ILD) or in left heart disease (PH-LHD).
Results
Riociguat is an orally active sGC-stimulator that has
been shown to have a favourable tolerability profile.
Consequently, Riociguat has been tested in small pilot
studies and in one phase II clinical trial in PAH and
CTEPH [1] as well as in PH-COPD [2] and PH-ILD [3].
The results of these studies suggest that Riociguat is a
potential treatment option for all of these conditions by
improving pulmonary hemodynamics. For PAH and
CTEPH a positive effect on clinical endpoints including
the six minute walking distance has also been demon-
strated [1]. As a result phase III clinical trials have been
launched for PAH (PATENT-trial), CTEPH (CHEST-
trial) and are preparation for the other diseases.
Conclusion
Based on the pharmacologic characteristic and on the
preliminary results from phase II studies, Riociguat is a
promising new drug which will hopefully be available
soon for the treatment of pulmonary hypertension in
different patient populations suffering from this
condition.
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